Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q4 FY26 results · Jan–Mar 2026
Supriya Lifescience reported revenue from operations of ₹276.53 crore (up 50.2% from Q4 FY25) and net profit of ₹74.23 crore (up 47.3% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a standalone basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 276.53 | 184.11 | +50.2% | 206.44 | +34.0% |
| Other income | 3.48 | 2.98 | +16.9% | 2.61 | +33.2% |
| Total income | 280.01 | 187.08 | +49.7% | 209.05 | +33.9% |
| Profit before tax | 92.13 | 64.06 | +43.8% | 66.92 | +37.7% |
| Net profit for the period | 74.23 | 50.38 | +47.3% | 49.67 | +49.4% |
| EPS, basic (₹) | 9.22 | 6.29 | +46.6% | 6.17 | +49.4% |
| Net margin (%) | 26.8 | 27.4 | 24.1 |
Standalone
- Filed with BSE
- 27 May 2026, 19:13 IST
- Board meeting
- 27 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE